IP Library Granted Patent US 11,155,796
Granted Patent B2
US 11,155,796 · App. 16/865,151 · Granted Oct 26, 2021

Compositions and methods for epigenome editing

Inventors: Charles A. Gersbach (Durham, NC); Isaac Hilton (Houston, TX)
Assignee: Duke University
C12N9/22C12N9/1029C12N15/11C12N15/63C12N15/85C12Y203/01048C07K2319/80C12N2310/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,155,796
App. No.
16/865,151
Granted
Oct 26, 2021
Kind
B2
Abstract

Disclosed herein are CRISPR/Cas9-based gene activation systems that include a fusion protein of a Cas9 protein and a protein having histone acetyltransferase activity, and methods of using said systems.

Claims (19)

1. An isolated polynucleotide encoding a fusion protein comprising two heterologous polypeptide domains,

wherein the first polypeptide domain comprises a Clustered Regularly Interspaced Short Palindromic Repeats associated (Cas) protein,

wherein the second polypeptide domain comprises a p300 histone acetyltransferase effector domain, and

wherein the fusion protein comprises the polypeptide sequence of SEQ ID NO: 140, SEQ ID NO: 141, or SEQ ID NO: 149.

2. The isolated polynucleotide of claim 1 , wherein the fusion protein activates transcription of a target gene by activating a regulatory element.

3. The isolated polynucleotide of claim 2 , wherein the regulatory element comprises a promoter of the target gene.

4. A vector comprising the isolated polynucleotide of claim 1 .

5. A kit comprising the isolated polynucleotide of claim 1 .

6. An isolated cell comprising the isolated polynucleotide of claim 1 .

7. An isolated polynucleotide encoding a fusion protein comprising two heterologous polypeptide domains,

wherein the first polypeptide domain comprises a Clustered Regularly Interspaced Short Palindromic Repeats associated (Cas) protein,

wherein the second polypeptide domain comprises a p300 histone acetyltransferase effector domain, and

wherein the first polypeptide domain comprises the polypeptide sequence of SEQ ID NO: 10 and the second polypeptide domain comprises the polypeptide sequence of SEQ ID NO: 3, or the first polypeptide domain comprises the polypeptide sequence of SEQ ID NO: 1 and the second polypeptide domain comprises the polypeptide sequence of SEQ ID NO: 2.

8. The isolated polynucleotide of claim 7 , wherein the fusion protein activates transcription of a target gene by activating a regulatory element.

9. The isolated polynucleotide of claim 8 , wherein the regulatory element comprises a promoter of the target gene.

10. The isolated polynucleotide of claim 7 , further comprising a linker connecting the first polypeptide domain to the second polypeptide domain.

11. A vector comprising the isolated polynucleotide of claim 7 .

12. A kit comprising the isolated polynucleotide of claim 7 .

13. An isolated cell comprising the isolated polynucleotide of claim 7 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2020
From: GERSBACH, CHARLES A.; HILTON, ISAAC
To: DUKE UNIVERSITY
Reel/Frame 052553/0984 →
Continuity (3)
Division 15549842
Provisional Application 62113569 · Feb 9, 2015
Related Publication 20200385695A1 · Dec 10, 2020
Cited By (6)
US 12,214,056 US 12,215,345 US 12,215,366 US 12,428,631 US 12,606,843 US 12,629,428